2021 Virtual Programme Speakers2022 speakers will be confirmed later in the year
Marco Del Chiaro, USA
The University of Colorado Cancer Center
Dr. Del Chiaro, Prof. of Surgery, Division Chief Surgical Oncology, and Dir. of Hepato-Pancreato-Biliary Program for University of Colorado, Anschutz Medical Campus in Denver, CO. He’s an academic surgical oncologist specialised in pancreatic diseases, having developed a new area of pancreatology as pre-emptive pancreatic surgery and surgical treatment of locally advanced pancreatic cancer.
With work in clinical research and in translational research, he has over 145 peer-reviewed articles in PubMed, several books and book chapters. A leader and founder of the largest Int’l consortium on pancreatic cystic tumours and PI of the new evidence-based guidelines for the tumour treatments.
Bjørn Edwin, Norway
Oslo University Hospital
Specialist in general surgery and gastrointestinal surgery. Professor in Minimal Invasive Surgery, Institute of Medicine, University of Oslo Section Leader, Section for Clinical Research, The Intervention Centre and affiliated to Department of HPB Surgery, Oslo University Hospital
Profile: HPB surgery, Endocrine surgery, Gastro-intestinal surgery, Urology and Pediatric surgery.
Main activity: Minimal Invasive HPB Surgery
Field of research: R&D in Minimal invasive therapy in HPB surgery: QoL, economic studies, immunological studies, genomic studies in bio bank (COMET study), survival etc. (Value based Health Care Research) R&D in minimal invasive therapy in colon surgery, urology and pediatric surgery. R&D of local ablation in liver malignancies, Cryotherapy, Radio frequency ablation and High Intensity focused ultrasound (HIFU). R&D of Implants of Biomedical material, (percutaneous implants for stomas.) R&D of Passive and Interactive navigation maps for liver surgery.
Main and co-supervisor for 13 PhD candidates plus 9 that have already defended their PhD
Teaching activity in laparoscopic general surgery and laparoscopic HPB surgery.
Published approx. 250 peer-reviewed articles, 5 book chapters and >450 congress abstracts/papers.
Peter Friend, United Kingdom
The University of Oxford
Professor Friend is a Fellow of the Royal College of Surgeons (Eng) and the Academy of Medical Sciences, and has a doctoral degree (MD) from the University of Cambridge. He is Professor of Transplantation, University of Oxford and Honorary Consultant Surgeon at Oxford University Hospitals NHS Foundation Trust, specialising in organ transplantation and hepatobiliary surgery.
He is also Director of the Oxford Transplant Centre and Fellow of Green Templeton College. Peter is a member of the Council of the Royal College of Surgeons and also of the International Transplantation Society. He is a past-president of the British Transplantation Society.
Mike Grocott, United Kingdom
The University Hospital of Southampton
Mike Grocott is the Professor of Anaesthesia and Critical Care Medicine at the University of Southampton, director designate of the Southampton NIHR Biomedical Research Centre (2020-2025) and an NIHR Senior Investigator.
He is an adjunct professor of Anaesthesiology at Duke University School of Medicine in North Carolina (USA) and honorary professor at University College London. Mike is vice-chair of the board of the UK national multidisciplinary Centre for Perioperative Care (CPOC) and was previously elected vice-president of the Royal College of Anaesthetists (2019-20). He chairs the board of the National Institute of Academic Anaesthesia (2018-22).
Nancy Kemeny, USA
Memorial Sloan Kettering Cancer Center
To improve outcomes for people with liver metastases, I’ve conducted research using regional chemotherapy (HAI). I was PI on CALGB study comparing HAI to systemic therapy in patients with unresectable liver metastases which demonstrated an increase in survival with HAI. I was also the PI on a randomized study of adjuvant HAI and systemic vs systemic after liver resection of colorectal metastases. The outcome was significant increase in hepatic DFS overall DRS with HAI. I’ve published > 400 papers, one of which demonstrated those who received HAI therapy after liver resection (treated > 2003) had a five-year survival of 78%.
Peter Kingham, USA
Memorial Sloan Kettering Cancer Center
Peter Kingham was appointed to Memorial Sloan Kettering Cancer Center’s Hepatopancreatobiliary Surgery Service in August, 2010. He is Associate Attending Surgeon. He is Director of the MSK International Surgical Oncology Fellowship and the Global Cancer Disparities Fellowship. He is Director of the MSK Global Cancer Disparity Initiative Program.
Martijn Meijerink, The Netherlands
Amsterdam University Medical Center
Interventional radiologist with interventional oncology as special field of expertise. Head fellowship and differentiation program interventional radiology for (resident) radiologists. Certified senior investigator interventional radiology and oncology.
Expert in open and percutaneous minimally invasive image guided treatments such as radiofrequency ablation, microwave ablation, irreversible electroporation (nanoknife), transarterial bland embolization, chemo- and Y90 radioembolization.
Society of Interventional Oncology (SIO) research committee chair. NVIR-NVvR (WCIR) research committee chair. Primary investigator of many prospective IO trials in the field of focal tumour ablation. Specific expertise in hepatopancreaticobiliary diseases and colorectal cancer national guideline committee member.
David Tuveson, USA
Cold Spring Harbor Laboratory
Dr. Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and the Chief Scientist for the Lustgarten Foundation.
David Tuveson’s laboratory uses murine and human models of pancreatic cancer to explore the fundamental biology of malignancy and thereby identify new diagnostic and treatment strategies. The lab’s approaches run the gamut from designing new model systems of disease to developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings. The lab’s studies make use of organoid cultures—three-dimensional cultures of normal or cancerous epithelia—as ex vivo models to probe cancer biology. Current projects in the lab explore changes in redox metabolism associated with pancreatic cancer tumorigenesis, dissect signaling by the Ras oncogene, discover new biomarkers of early pancreas cancer, and identify mechanisms of cross-talk between pancreatic cancer cells and the tumor stroma. Novel treatment approaches suggested by these studies are then tested by performing therapeutic experiments in mouse models. To dissect molecular changes associated with pancreatic tumorigenesis, the Tuveson lab has generated a large collection of human patient-derived organoid models. By measuring the therapeutic sensitivities of patient-derived organoids, the lab is working to identify novel strategies to treat patients as well as markers of therapeutic response. The Tuveson Laboratory maintains strong links to clinical research, and the ultimate goal is confirmation of preclinical findings in early-phase trials. Collectively, the lab’s bench-to-bedside approach is codified as the “Cancer Therapeutics Initiative,” and this initiative will provide these same approaches to the entire CSHL cancer community.
Caroline Verbeke, Norway
Oslo University Hospital
Caroline Verbeke trained in Histopathology at the University Hospital Antwerp (Belgium) and Mannheim/Heidelberg (Germany), following which she worked at the University of Chicago, St James’s University Hospital Leeds (UK) and Karolinska University Hospital, Stockholm (Sweden).
Since 2014, she works as a Professor and Consultant Histopathologist at the University of Oslo/ Oslo University Hospital. She has 20+ years of experience in pancreatic pathology and is actively involved at an international level in the development of diagnostic data sets and guidelines for the reporting of pancreatic cancer. She is interested in tumour heterogeneity and the characterisation of pancreatic cancer following neoadjuvant treatment.
Chris Wolfgang, USA
NYU School of Medicine
Chief of Hepatobiliary and Pancreatic Surgery
Professor of Surgery
NYU School of Medicine and NYU Langone Health System
Luca Aldrighetti, Italy
Luca Aldrighetti is Director of Hepatobiliary Surgery and Associate Professor of Surgery of Vita-Salute University, Milan, Italy. Scientific Director of the Italian Group of Minimally Invasive Liver Surgery (IGoMILS). Council Member of ILLS. Clinical and research activities are focused on liver surgery and hepatic tumours, with a personal series of more than 3500 liver resections, more than 1300 of which performed laparoscopically.
He has published more than 300 papers, current H index is 48. He continues with teaching and tutoring activities in a number of national and international courses in both open and laparoscopic liver surgery.
Peter Allen, USA
Duke Cancer Center
Dr. Peter J. Allen is Professor of Surgery and Chief of the Division of Surgical Oncology Division at Duke University. He also serves as the Chief of Surgery at the Duke Cancer Institute.
He is originally from the state of Maine, received his undergraduate degree from Harvard University, and his medical degree from Dartmouth. Dr Allen performed his general surgical residency at Walter Reed Army Medical Center in Washington D.C., and performed both research and clinical fellowships at Memorial Sloan Kettering. Following his training, he returned to Walter Reed where he practiced general surgical oncology. During his time as a surgical attending at Walter Reed, Dr. Allen was deployed to Iraq where he spent one year as a surgeon on a forward surgical team and was awarded the combat medical badge. Dr. Allen was recruited to Memorial Sloan-Kettering Cancer Center in 2003, and for 13 years he led the surgical efforts in the treatment of neoplastic diseases of the pancreas. During his time at Sloan Kettering, Dr. Allen held the Murray F Brennan Chair in Surgery and served as the Vice Chair for Surgical Services and the Associate Director for Clinical programs in the Rubenstein Center for Pancreatic Research.
Dr. Allen joined the Duke team in 2018 as the chief of the Division of Surgical Oncology, and the Chief of Surgery in the Duke Cancer Institute. His clinical and research efforts have been focused on the development of novel diagnostic and therapeutic approaches to invasive and pre-invasive lesions of the pancreas, with a particular focus on intraductal papillary mucinous neoplasms. His research has been funded by numerous organizations and he has maintained NIH funding since 2009.
Marc Bemelmans, The Netherlands
Marc Bemelmans completed Medical School at the Maastricht University after which he did a research fellowship on Transplant Surgery at the University of Madison, Wisconsin under supervision of Prof J Southard and Prof FO Belzer. After his surgical education in the Netherlands in 1999 he did a fellowship on HPB surgery from end 1999 till begin 2001 at the University of Paris, Paul Brousse Hospital under the supervision of Prof H Bismuth where he was further educated in liver surgery and transplant surgery. He performed several management tasks such as board member of the Dutch Society of research coming from surgical residents in the Netherlands, treasurer and board member of the Dutch Society of GI surgery, Treasurer and board member of the Dutch society of Surgery and is momentarily a Compagnon Hepatobiliare appointed by Prof H Bismuth.
He is now a HPB and sarcoma surgeon in the University hospital of Maastricht and the Uniklink Aachen en is also Chairman of the board of sarcoma surgery in the south east of the Netherlands (ONCOZON)
His research interest includes liver regeneration, Klatskin tumors, robotic liver surgery and complex sarcoma surgery; His research includes liver regeneration, predicting biology of cancer, Iknife techniques for surgery (especially in sarcoma surgery)
Nicolas Demartines, Switzerland
University Hospital CHUV
Professor of Surgery, and Chair Surgery at the University Hospital in Lausanne Switzerland. Member of the French Academy of Surgery in Paris, guest professor at the University Hospital of Lanzhou and honorary Fellow of the ASGBI, the Chinese College of Surgeons and the French Association of Surgery.
Focus on oncologic surgery, mainly hepato-pancreatico-biliary. Research includes innovative treatment of liver metastasis and peri-operative management (ERAS). Chair implementation of the ERAS Society. Faculty at IRCAD-EITS. Vice-Chair of the council of the Society of British Journal of Surgery. Expert at the French National Institute for Cancer (INCA).
Ashley Dennison, UK
University Hospitals of Leicester NHS Trust
Åsmund Fretland, Norway
Oslo University Hospital
Dr. Fretland is a consultant HPB surgeon at Oslo University Hospital, with a special interest in minimally invasive surgery and clinical trials.
Mo Abu Hilal, Italy
- Liver Surgery (liver cancer and benign liver conditions)
- Pancreatic Surgery (pancreatic cancer and benign Pancreatic conditions)
- Biliary and Laparoscopic (Keyhole) Surgery (laparoscopic cholecystectomy, gallstone, bile duct cancer and bile duct benign conditions)
I consider my sub-speciality as one of the most complex surgical specialities, where good knowledge, advanced surgical skills, hard work, dedication and enthusiasm are a must to achieve excellent outcome and to deliver a high standard of care. However, I believe that good communication, empathy and mutual trust and respect between me and my patients are the essential pilots to reach clinical excellence and improve patient’s experience. I have a strong academic interest and have published a large number of scientific papers, book chapters, scientific reviews and abstracts. I strongly feel that every clinician is ethically and professional expected to participate to the development of evidence based medicine through clinical and experiment research. I will always offer my patients the best treatment based on the strongest scientific evidence on which I am continuously updated. I believe that the best surgical procedure is the right procedure, for the right indication, by the right surgeon, with the right outcome. Therefore, I will offer surgery only if I believe this to be in the best patients interest. I will explain to my patients all the benefits and risks associated with the surgical procedure and help them to take decision supported by evidences and results. If I think that the procedure needed is not within my surgical territory, I will make sure that patients are referred to right expertise.
David Ianitti, USA
Atrium Health Carolinas Medial Center (CMC)
Dr Iannitti is Professor of Surgery, Program Director of the AHPBA HPB Surgery Fellowship and Chief of the Division of HPB Surgery at AtriumHealth – Carolinas Medical Center in Charlotte, NC, USA.
Choon Hyuck David Kwon, USA
Dr. Kwon completed all his medical education and training in Korea and worked as attending at Samsung Medical Center for 14 years where he developed one of the largest laparoscopic liver programs in the world.
He moved to the US in 2017 and is currently the Director of Laparoscopic Liver Surgery at Cleveland Clinic where he successfully launched a laparoscopic donor program in 2019. It has now become one of the largest programs in the US.
Rob Padbury, Australia
Director of Surgery and Perioperative Medicine in the Southern Adelaide Local Health Network, SA Health. Predominant clinical practice interest is HPB Surgery. Predominant leadership interest is clinical practice improvement, clinical standardisation and reducing variation with clinical protocols. Research interests are predominantly clinical and epidemiological, and has 111 publications. Chairman, State Surgical Taskforce from inception until April 2015. Director, SA Centre of Healthcare Improvement 2008-2013. Undertook review of Tasmanian Surgical Services 2014 and Western Australian upper GI Surgery in 2016.
Quintus Molenaar, The Netherlands
University Medical Center Utrecht
John Primrose, UK
The University of Southampton
Professor of Surgery at the University of Southampton with a clinical interest in HPB surgery. A member of the UK Academy of Medical Sciences and an NIHR Senior Investigator. Chief investigator of a number of clinical trails that have changed practice globally and most trial have a major translational focus. Chairs or is a member of several grant funding bodies and presently a NICE committee chair. Past President of the Association of Surgeon of Great Britain and Ireland.
Nick O’Rourke, Australia
Royal Brisbane Hospital
Nick is head of HPB surgery at Royal Brisbane Hospital with a long interest in laparoscopic approaches to HPB problems.
Siân Pugh, UK
Siân’s research is focused on understanding the determinants of progression in colorectal cancer and she has a particular interest in colorectal liver metastasis. She is an investigator for the New EPOC study and has led both the latter trial logistics and translational outputs.
Originally Siân intended to combine a research career with general surgery and successfully pursued this to the level of ST4, following which she went on to secure a prestigious MRC clinical research training fellowship. She has subsequently changed her clinical focus and is currently training in medical oncology at Addenbrooke’s Hospital, Cambridge, United Kingdom.
Myrddin (Merv) Rees, UK
Basingstoke and North Hampshire Hospital
Myrddin (Merv) Rees is a consultant hepatobiliary surgeon at Basingstoke and North Hampshire Hospital. After surgical training at St George’s Hospital, London he spent 2 years at the Oschner Clinic, New Orleans.
In 1986, after a period with Professor Johannes Scheele in Erlangen, he established a hepatic resection practice with particular reference to colorectal secondaries. The unit performs more than 175 hepatectomies annually, with a total to date of over 3,500 resections of which over 3,000 are for colorectal metastases. He has co-authored over 100 surgical papers. He is a Past President of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland.
Go Wakabayashi, Japan
Ageo Central General Hospital
Go Wakabayashi, earned his degrees from Keio University School of Medicine, Tokyo Japan. He trained at Department of Surgery at Massachusetts General Hospital and Harvard Medical School. After working as an Assistant Professor at Department of Surgery, Keio University School of Medicine, he got appointed as Professor and Chairman of Department of Surgery at Iwate Medical University School of Medicine in 2005. From April 2015, he was recruited as Director of Center for Advanced Treatment of HPB Disease, Chief of Surgical Services, and Deputy Director at Ageo Central General Hospital, which is a flagship hospital among 6,000 beds hospital complex near Tokyo.
His expertise includes Hepato-Pancreatic Biliary Surgery, liver transplantation, and laparoscopic surgery. He has operated more than 150 cases of living liver transplantation and over 3000 cases of HPB surgery and laparoscopic surgery. His publications are over 300 peer review articles and book chapters related to HPB surgery, liver transplantation, and laparoscopic surgery. He was awarded Gold Medal of Video Olympics at The World Congress of Endoscopic Surgery 1996. He also practices conventional HPB surgery and aggressive surgery as well. He holds numerous important positions in Japanese and international surgical societies. He is the President of the International Laparoscopic Liver Society for 2019 to 2021.
Steve Wigmore, UK
The University of Edinburgh
Steve Wigmore is the Regius Professor and Head of the Department of Clinical Surgery at the Royal Infirmary of Edinburgh. He is also Surgeon to the Queen and Editor in Chief of HPB the official journal of the IHPBA. He is experienced in HPB surgery and liver transplantation.
Lotte Boxhoorm, The Netherlands
Amsterdam University Medical Center
Burak Görgec, The Netherlands
Amsterdam University Medical Center
Jan Heil, Germany
The University Hospital of Frankfurt
Lynn Nooijen, The Netherlands
Amsterdam University Medical Center